CA-CONFLUENT
12.5.2021 09:02:04 CEST | Business Wire | Press release
Confluent, Inc. , the platform to set data in motion, today announced Confluent for Kubernetes , the first platform purpose-built to bring cloud-native capabilities to data streams in private infrastructures. To make it easier and faster to harness the value of data in motion across an entire organization, Confluent drew on its expertise managing thousands of Apache Kafka® clusters in Confluent Cloud to offer the same cloud-native experience for on-premises environments. These cloud-native capabilities are key to running modern data platforms and are now available wherever an organization’s applications and data reside. Within minutes, it’s now possible to build a private cloud Kafka service that powers applications that are increasingly critical to how organizations thrive.
To win in today’s global economy, organizations must deliver exceptional customer experiences and data-driven, backend operations. This requires the ability to react, respond, and adapt to a continuous, ever-changing flow of data from across an organization in real time. This has driven the rapid rise of Kafka as a key enabler to helping companies cut across silos and process the flow of business events as they happen. However, given the high level of technical complexity, need for constant monitoring, and time-consuming custom tooling, self-managing Kafka is difficult and often takes large teams of specialized professionals. These challenges can result in costly project delays and inefficient resource investments, holding organizations back as they compete to innovate and win in a digital-first world.
“To compete in the digital realm, organizations need to quickly deliver personalized customer experiences and real-time operations, which are only possible with access to data from all environments and cloud-native advantages,” said Ganesh Srinivasan, Chief Product and Engineering Officer, Confluent. “For organizations that need to operate on premises, we’re bringing the benefits of cloud computing to their private infrastructure with Confluent for Kubernetes. Now, any company can build a private cloud service to move data across their business regardless of its environment.”
Confluent for Kubernetes – Bringing Benefits From the Leading Data in Motion Cloud Platform to On-Premises Environments
With the launch of Confluent for Kubernetes, Confluent brings together the cloud-native advantages learned from Confluent Cloud with the control and customization from self-managing their private infrastructure in on-premises environments. So whether an organization is transitioning to the cloud or needs to keep workloads on premises, they can take full advantage of Confluent for Kubernetes’ cloud-native capabilities, including a declarative API to deploy and operate Confluent. The platform also makes moving applications to the public cloud easier by seamlessly migrating workloads to wherever your business needs them with the ability to connect and share data with Confluent Cloud. By reimagining what is possible for private infrastructure with the capabilities of modern cloud computing, it is easier than ever for organizations to build and manage a private cloud Kafka service for moving data across a business.
- Enhanced reliability – As a cloud-native system, Confluent for Kubernetes intelligently detects if a process fails and will automatically restart processes or reschedule as necessary. Automated rack awareness spreads replicas of a partition across different racks, improving the availability of your brokers and limiting the risk of data loss. With automated reliability, organizations can minimize the risk of business disruption, reduce downtime costs, and limit data loss.
- Automated elasticity – Meet changing business demands with the ability to scale up using API-driven operations. The platform will automatically generate configurations, schedule and run new broker processes, and ensure data is balanced across brokers so that clusters can be efficiently utilized. With the ability to spin up and down Confluent clusters, organizations can control infrastructure costs while quickly scaling to meet their business needs.
- Simplified infrastructure management – A core concept of the cloud-native paradigm is the ability to focus on higher value activities that create business value rather than performing complex sequences of low-level infrastructure-related operations. Confluent for Kubernetes extends the Kubernetes API, enabling organizations to define the desired high-level state of clusters rather than manage all the low-level details. This infrastructure-as-code approach reduces operational burden and achieves a faster time to value, while enhancing security with standards that can be easily and consistently deployed across an organization.
Kafka Summit Europe 2021
Tune into Confluent Co-founder and CEO Jay Kreps’ keynote at Kafka Summit Europe on May 12 at 8:00 a.m. GMT to learn more about today’s news. Register now: https://kafkasummit.io/
For a deep dive into Confluent for Kubernetes, don’t miss this Kafka Summit Europe lightning talk happening today at 1 p.m. GMT: https://www.kafka-summit.org/sessions/gitops-for-kafka-with-confluent-for-kubernetes
Additional Resources
- For more details on how Confluent for Kubernetes works, check out our blog: https://www.confluent.io/blog/confluent-for-kubernetes-offers-cloud-native-kafka-automation/
- See how Confluent is helping its customers transform their businesses: https://www.confluent.io/customers/
- Learn more about Confluent: https://www.confluent.io/
- Join Confluent and apply for one of its open positions: https://www.confluent.io/careers/
About Confluent
Confluent is pioneering a fundamentally new category of data infrastructure focused on data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io .
The preceding outlines our general product direction and is not a commitment to deliver any material, code, or functionality. The development, release, timing, and pricing of any features or functionality described may change. Customers should make their purchase decisions based upon services, features, and functions that are currently available. Confluent and associated marks are trademarks or registered trademarks of Confluent, Inc.
Apache® and Apache Kafka® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
